2012-09-16 07:35:20 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Markets Direct's, 'Adenocarcinoma - Pipeline Review, H2 2012', provides an overview of the Adenocarcinoma therapeutic pipeline. This report provides information on the therapeutic development for Adenocarcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adenocarcinoma. 'Adenocarcinoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/463891_adenocarcinoma_pipeline_review_h2_201 ..


Note*: Certain sections in the report may be removed or altered based on the availability and

relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Adenocarcinoma.
* A review of the Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Adenocarcinoma pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Adenocarcinoma pipeline depth and focus of Adenocarcinoma therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Adenocarcinoma Therapeutic Products under Development, Key Players in Adenocarcinoma Therapeutics, Adenocarcinoma Pipeline Overview, Adenocarcinoma Pipeline, Adenocarcinoma Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Adenocarcinoma Overview
Therapeutics Development
An Overview of Pipeline Products for Adenocarcinoma
Adenocarcinoma Therapeutics under Development by Companies
Adenocarcinoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Adenocarcinoma Therapeutics - Products under Development by Companies
Adenocarcinoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Adenocarcinoma Therapeutics Development
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Sanofi-Aventis
Eli Lilly and Company
Gilead Sciences, Inc.
BioLineRx, Ltd.
Novartis AG
Astellas Pharma Inc.
Pfizer Inc.
Aduro BioTech
Celgene Corporation
Merck KGaA
Novartis Pharmaceuticals Corporation
Alchemia Limited
Celldex Therapeutics, Inc.
Lorus Therapeutics Inc
AVAX Technologies, Inc.
Oncolytics Biotech Inc.
Threshold Pharmaceuticals, Inc.
GANYMED Pharmaceuticals AG
Merrimack Pharmaceuticals, Inc.
Axcentua Pharmaceuticals AB
BioCancell Therapeutics, Inc.
Kinex Pharmaceuticals, LLC
Adenocarcinoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
HyDox - Drug Profile
CDX-1127 - Drug Profile
ASG-5ME - Drug Profile
LOR-1284 - Drug Profile
MSC1936369B - Drug Profile
OVax - Drug Profile
MM-398 - Drug Profile
IMAB362 - Drug Profile
Pazopanib + Doxil - Drug Profile
IMC-C225 + Gemcitabine - Drug Profile
Vorinostat + Fluorouracil - Drug Profile
Efavirenz - Drug Profile
Carboplatin + Taxol + RAD001 - Drug Profile
Docetaxel + Oxaliplatin + Capecitabine + Fluorouracil + Radiation Therapy - Drug Profile
OSI-774 + Bevacizumab - Drug Profile
Abraxane + Gemzar - Drug Profile
RAD001 + Cetuximab + Irinotecan - Drug Profile
PF-02341066 + Erlotinib - Drug Profile
Reolysin + Gemzar - Drug Profile

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463891&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.